Selatinib

Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1].

Product Specifications

CAS Number

[1275595-86-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/selatinib.html

Purity

98.56

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C)CCNCC1=CC=C(O1)C2=CC3=C(N=CN=C3C=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5

Molecular Formula

C29H26ClFN4O3S

Molecular Weight

565.06

Precautions

H315, H319, H320

References & Citations

[1]Meng-Na Wang, et al. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Invest New Drugs. 2020 Dec;38 (6) :1826-1835.